Cargando…

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis

OBJECTIVES: The objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK) of orally administered rifampicin, to derive summary estimates of rifampicin PK parameters at standard dosages and to compare these with summary estimates for higher dosages. METHODS: A sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stott, K E, Pertinez, H, Sturkenboom, M G G, Boeree, M J, Aarnoutse, R, Ramachandran, G, Requena-Méndez, A, Peloquin, C, Koegelenberg, C F N, Alffenaar, J W C, Ruslami, R, Tostmann, A, Swaminathan, S, McIlleron, H, Davies, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105874/ https://www.ncbi.nlm.nih.gov/pubmed/29701775 http://dx.doi.org/10.1093/jac/dky152

Ejemplares similares

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
por: Sturkenboom, Marieke G. G., et al.
Publicado: (2021)

Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
por: Ruslami, Rovina, et al.
Publicado: (2022)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
por: Jacobs, Tom G, et al.
Publicado: (2020)

Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications
por: Court, R., et al.
Publicado: (2018)

The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy
por: Decloedt, Eric H., et al.
Publicado: (2012)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB
por: Taneja, R., et al.
Publicado: (2023)

Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients
por: Mtabho, Charles M, et al.
Publicado: (2019)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2023)

Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study
por: Ghimire, Samiksha, et al.
Publicado: (2023)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials
por: Svensson, Elin M, et al.
Publicado: (2019)

Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients
por: Ramachandran, Geetha, et al.
Publicado: (2013)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial
por: Espinosa-Pereiro, Juan, et al.
Publicado: (2022)

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
por: Seijger, Charlotte, et al.
Publicado: (2019)

UNITE4TB: a new consortium for clinical drug and regimen development for TB
por: Boeree, M. J., et al.
Publicado: (2021)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
por: Shin, Yesong, et al.
Publicado: (2022)

Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania
por: Mohamed, Sagal, et al.
Publicado: (2021)

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients
por: te Brake, Lindsey H.M., et al.
Publicado: (2018)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Clinical standards for the management of adverse effects during treatment for TB
por: Singh, K. P., et al.
Publicado: (2023)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

Clinical standards for the dosing and management of TB drugs
por: Alffenaar, J. W. C., et al.
Publicado: (2022)

Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19
por: Mohr-Holland, E., et al.
Publicado: (2021)

Rifampicin treatment of persistently elevated benzodiazepine metabolites in a comatose patient
por: Panday, P. V. Nannan, et al.
Publicado: (2009)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Current research toward optimizing dosing of first-line antituberculosis treatment
por: McIlleron, Helen, et al.
Publicado: (2018)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Clinical standards for drug-susceptible pulmonary TB
por: Akkerman, O. W., et al.
Publicado: (2022)

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation
por: Millard, James, et al.
Publicado: (2018)

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV
por: Chabala, Chishala, et al.
Publicado: (2023)

eHealth in TB clinical management
por: Margineanu, I., et al.
Publicado: (2022)

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers
por: Liu, Yong, et al.
Publicado: (2014)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d6i49sutgem465vqj8ss38ps3c